Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C.
PMID: 34321278
Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28.

PURPOSE: The heterogeneity of response to anti-HER2 agents represents a major challenge in patients with HER2-positive breast cancer. To better understand the sensitivity and resistance to trastuzumab and lapatinib, we investigated the role of copy number aberrations (CNA) in...

Cite
Venet D, Rediti M, Maetens M, et al. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021;27(20):5607-5618doi: 10.1158/1078-0432.CCR-21-1317.
Venet, D., Rediti, M., Maetens, M., Fumagalli, D., Brown, D. N., Majjaj, S., Salgado, R., Pusztai, L., Harbeck, N., El-Abed, S., Wang, Y., Saura, C., Gomez, H., Semiglazov, V. F., de Azambuja, E., Huober, J., Nuciforo, P., Di Cosimo, S., Piccart, M., Loi, S., Rothé, F., & Sotiriou, C. (2021). Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5607-5618. https://doi.org/10.1158/1078-0432.CCR-21-1317
Venet, David, et al. "Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5607-5618. doi: https://doi.org/10.1158/1078-0432.CCR-21-1317
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28. PMID: 34321278.
Copy Download .nbib Format: NLM
Hereditary breast-ovarian cancer syndrome in Russia.

Acta naturae

Sokolenko AP, Iyevleva AG, Mitiushkina NV, Suspitsin EN, Preobrazhenskaya EV, Kuligina ESh, Voskresenskiy DA, Lobeiko OS, Krylova NY, Gorodnova TV, Buslov KG, Bit-Sava EM, Dolmatov GD, Porhanova NV, Polyakov IS, Abysheva SN, Katanugina AS, Baholdin DV, Yanus GA, Togo AV, Moiseyenko VM, Maximov SY, Semiglazov VF, Imyanitov EN.
PMID: 22649661
Acta Naturae. 2010 Oct;2(4):31-5.

Hereditary breast-ovarian cancer syndrome contributes to as much as 5-7% of breast cancer (BC) and 10-15% of ovarian cancer (OC) incidence. Mutations in the "canonical" genesBRCA1andBRCA2occur in 20-30% of affected pedigrees. In addition toBRCA1andBRCA2 mutations, germ-line lesions in theCHEK2,NBS1,...

Cite
Sokolenko AP, Iyevleva AG, Mitiushkina NV, et al. Hereditary breast-ovarian cancer syndrome in Russia. Acta Naturae. 2010;2(4):31-5
Sokolenko, A. P., Iyevleva, A. G., Mitiushkina, N. V., Suspitsin, E. N., Preobrazhenskaya, E. V., Kuligina, E. S. h., Voskresenskiy, D. A., Lobeiko, O. S., Krylova, N. Y., Gorodnova, T. V., Buslov, K. G., Bit-Sava, E. M., Dolmatov, G. D., Porhanova, N. V., Polyakov, I. S., Abysheva, S. N., Katanugina, A. S., Baholdin, D. V., Yanus, G. A., Togo, A. V., Moiseyenko, V. M., Maximov, S. Y., Semiglazov, V. F., & Imyanitov, E. N. (2010). Hereditary breast-ovarian cancer syndrome in Russia. Acta naturae, 2(4), 31-5.
Sokolenko, A P, et al. "Hereditary breast-ovarian cancer syndrome in Russia." Acta naturae vol. 2,4 (2010): 31-5.
Sokolenko AP, Iyevleva AG, Mitiushkina NV, Suspitsin EN, Preobrazhenskaya EV, Kuligina ESh, Voskresenskiy DA, Lobeiko OS, Krylova NY, Gorodnova TV, Buslov KG, Bit-Sava EM, Dolmatov GD, Porhanova NV, Polyakov IS, Abysheva SN, Katanugina AS, Baholdin DV, Yanus GA, Togo AV, Moiseyenko VM, Maximov SY, Semiglazov VF, Imyanitov EN. Hereditary breast-ovarian cancer syndrome in Russia. Acta Naturae. 2010 Oct;2(4):31-5. PMID: 22649661; PMCID: PMC3347586.
Copy Download .nbib Format: NLM
Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.

Hereditary cancer in clinical practice

Sokolenko AP, Voskresenskiy DA, Iyevleva AG, Bit-Sava EM, Gutkina NI, Anisimenko MS, Yu Sherina N, Mitiushkina NV, Ulibina YM, Yatsuk OS, Zaitseva OA, Suspitsin EN, Togo AV, Pospelov VA, Kovalenko SP, Semiglazov VF, Imyanitov EN.
PMID: 19338681
Hered Cancer Clin Pract. 2009 Jan 26;7(1):2. doi: 10.1186/1897-4287-7-2.

Although the probability of both parents being affected by BRCA1 mutations is not negligible, such families have not been systematically described in the literature. Here we present a large breast-ovarian cancer family, where 3 sisters and 1 half-sister inherited...

Cite
Sokolenko AP, Voskresenskiy DA, Iyevleva AG, et al. Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. Hered Cancer Clin Pract. 2009;7(1):2doi: 10.1186/1897-4287-7-2.
Sokolenko, A. P., Voskresenskiy, D. A., Iyevleva, A. G., Bit-Sava, E. M., Gutkina, N. I., Anisimenko, M. S., Yu Sherina, N., Mitiushkina, N. V., Ulibina, Y. M., Yatsuk, O. S., Zaitseva, O. A., Suspitsin, E. N., Togo, A. V., Pospelov, V. A., Kovalenko, S. P., Semiglazov, V. F., & Imyanitov, E. N. (2009). Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. Hereditary cancer in clinical practice, 7(1), 2. https://doi.org/10.1186/1897-4287-7-2
Sokolenko, Anna P, et al. "Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing." Hereditary cancer in clinical practice vol. 7,1 (2009): 2. doi: https://doi.org/10.1186/1897-4287-7-2
Sokolenko AP, Voskresenskiy DA, Iyevleva AG, Bit-Sava EM, Gutkina NI, Anisimenko MS, Yu Sherina N, Mitiushkina NV, Ulibina YM, Yatsuk OS, Zaitseva OA, Suspitsin EN, Togo AV, Pospelov VA, Kovalenko SP, Semiglazov VF, Imyanitov EN. Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. Hered Cancer Clin Pract. 2009 Jan 26;7(1):2. doi: 10.1186/1897-4287-7-2. PMID: 19338681; PMCID: PMC2653717.
Copy Download .nbib Format: NLM
Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Novikov SN, Kanaev SV, Semiglazov VF, Jukova LA, Krzhivitckiy PI.
PMID: 25535581
Rep Pract Oncol Radiother. 2014 Jul 19;20(1):27-31. doi: 10.1016/j.rpor.2014.06.001. eCollection 2015 Jan.

AIM AND BACKGROUND: Radiotherapy being an essential part of breast cancer treatment, we evaluate various radiotherapy strategies in patients with breast cancer.MATERIALS AND METHODS: Lymph node (LN) scintigraphy was performed in 172 primary patients with BC. LN visualization started...

Cite
Novikov SN, Kanaev SV, Semiglazov VF, et al. Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields. Rep Pract Oncol Radiother. 2014;20(1):27-31doi: 10.1016/j.rpor.2014.06.001.
Novikov, S. N., Kanaev, S. V., Semiglazov, V. F., Jukova, L. A., & Krzhivitckiy, P. I. (2015). Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 20(1), 27-31. https://doi.org/10.1016/j.rpor.2014.06.001
Novikov, Sergey Nikolaevich, et al. "Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields." Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology vol. 20,1 (2015): 27-31. doi: https://doi.org/10.1016/j.rpor.2014.06.001
Novikov SN, Kanaev SV, Semiglazov VF, Jukova LA, Krzhivitckiy PI. Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields. Rep Pract Oncol Radiother. 2014 Jul 19;20(1):27-31. doi: 10.1016/j.rpor.2014.06.001. eCollection 2015 Jan. PMID: 25535581; PMCID: PMC4268592.
Copy Download .nbib Format: NLM
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.

Molecular oncology

Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E.
PMID: 34816585
Mol Oncol. 2021 Nov 23; doi: 10.1002/1878-0261.13141. Epub 2021 Nov 23.

As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage therapy, are needed. Herein, we evaluated the 41-gene classifier...

Cite
Triulzi T, Bianchini G, Di Cosimo S, et al. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol. 2021;doi: 10.1002/1878-0261.13141.
Triulzi, T., Bianchini, G., Di Cosimo, S., Pienkowski, T., Im, Y. H., Bianchi, G. V., Galbardi, B., Dugo, M., De Cecco, L., Tseng, L. M., Liu, M. C., Bermejo, B., Semiglazov, V., Viale, G., de la Haba-Rodriguez, J., Oh, D. Y., Poirier, B., Valagussa, P., Gianni, L., & Tagliabue, E. (2021). The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular oncology, . https://doi.org/10.1002/1878-0261.13141
Triulzi, Tiziana, et al. "The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13141
Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol. 2021 Nov 23; doi: 10.1002/1878-0261.13141. Epub 2021 Nov 23. PMID: 34816585.
Copy Download .nbib Format: NLM
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.

Molecular oncology

Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Valeria Bianchi G, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E.
PMID: 34816585
Mol Oncol. 2021 Nov 23; doi: 10.1002/1878-0261.13141. Epub 2021 Nov 23.

As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting post-surgical salvage therapy, are needed. Herein, we evaluated the 41-gene classifier...

Cite
Triulzi T, Bianchini G, Di Cosimo S, et al. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol. 2021;doi: 10.1002/1878-0261.13141.
Triulzi, T., Bianchini, G., Di Cosimo, S., Pienkowski, T., Im, Y. H., Valeria Bianchi, G., Galbardi, B., Dugo, M., De Cecco, L., Tseng, L. M., Liu, M. C., Bermejo, B., Semiglazov, V., Viale, G., de la Haba-Rodriguez, J., Oh, D. Y., Poirier, B., Valagussa, P., Gianni, L., & Tagliabue, E. (2021). The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular oncology, . https://doi.org/10.1002/1878-0261.13141
Triulzi, Tiziana, et al. "The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13141
Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Valeria Bianchi G, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol. 2021 Nov 23; doi: 10.1002/1878-0261.13141. Epub 2021 Nov 23. PMID: 34816585.
Copy Download .nbib Format: NLM
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology

Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M.
PMID: 30624616
Ann Oncol. 2019 Jun 01;30(6):1017. doi: 10.1093/annonc/mdy529.

No abstract available.

Cite
Baselga J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2019;30(6):1017doi: 10.1093/annonc/mdy529.
Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V. F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R. H., Matera, J., Azarnia, N., Hudis, C. A., & Rozencweig, M. (2019). Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 30(6), 1017. https://doi.org/10.1093/annonc/mdy529
Baselga, J, et al. "Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer." Annals of oncology : official journal of the European Society for Medical Oncology vol. 30,6 (2019): 1017. doi: https://doi.org/10.1093/annonc/mdy529
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2019 Jun 01;30(6):1017. doi: 10.1093/annonc/mdy529. PMID: 30624616; PMCID: PMC7340185.
Copy Download .nbib Format: NLM
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Annals of oncology : official journal of the European Society for Medical Oncology

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.
PMID: 29733336
Ann Oncol. 2018 Oct 01;29(10):2153. doi: 10.1093/annonc/mdx806.

No abstract available.

Cite
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018;29(10):2153doi: 10.1093/annonc/mdx806.
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H. J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S. Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D. F., Huang, C. S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K. C., Pagani, O., Partridge, A. H., Pritchard, K., Ro, J., Rutgers, E. J. T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T. J., & Xu, B. (2018). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of oncology : official journal of the European Society for Medical Oncology, 29(10), 2153. https://doi.org/10.1093/annonc/mdx806
Curigliano, G, et al. "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017." Annals of oncology : official journal of the European Society for Medical Oncology vol. 29,10 (2018): 2153. doi: https://doi.org/10.1093/annonc/mdx806
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01;29(10):2153. doi: 10.1093/annonc/mdx806. PMID: 29733336; PMCID: PMC6887963.
Copy Download .nbib Format: NLM
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C.
PMID: 34321278
Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28.

PURPOSE: The heterogeneity of response to anti-HER2 agents represents a major challenge in patients with HER2-positive breast cancer. To better understand the sensitivity and resistance to trastuzumab and lapatinib, we investigated the role of copy number aberrations (CNA) in...

Cite
Venet D, Rediti M, Maetens M, et al. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021;27(20):5607-5618doi: 10.1158/1078-0432.CCR-21-1317.
Venet, D., Rediti, M., Maetens, M., Fumagalli, D., Brown, D. N., Majjaj, S., Salgado, R., Pusztai, L., Harbeck, N., El-Abed, S., Wang, Y., Saura, C., Gomez, H., Semiglazov, V. F., de Azambuja, E., Huober, J., Nuciforo, P., Di Cosimo, S., Piccart, M., Loi, S., Rothé, F., & Sotiriou, C. (2021). Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5607-5618. https://doi.org/10.1158/1078-0432.CCR-21-1317
Venet, David, et al. "Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5607-5618. doi: https://doi.org/10.1158/1078-0432.CCR-21-1317
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28. PMID: 34321278.
Copy Download .nbib Format: NLM
Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer.

Cancers

Nazarova I, Slyusarenko M, Sidina E, Nikiforova N, Semiglazov V, Semiglazova T, Aigner A, Rybakov E, Malek A.
PMID: 34359806
Cancers (Basel). 2021 Aug 03;13(15). doi: 10.3390/cancers13153905.

PURPOSE: Developing new and efficient approaches for the early diagnosis of colorectal cancer (CRC) is an important issue. Circulating extracellular nanovesicles (ENVs) present a promising class of cancer markers. Cells of well-differentiated adenocarcinomas retain the molecular characteristics of colon...

Cite
Nazarova I, Slyusarenko M, Sidina E, et al. Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer. Cancers (Basel). 2021;13(15)doi: 10.3390/cancers13153905.
Nazarova, I., Slyusarenko, M., Sidina, E., Nikiforova, N., Semiglazov, V., Semiglazova, T., Aigner, A., Rybakov, E., & Malek, A. (2021). Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer. Cancers, 13(15), . https://doi.org/10.3390/cancers13153905
Nazarova, Inga, et al. "Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer." Cancers vol. 13,15 (2021). doi: https://doi.org/10.3390/cancers13153905
Nazarova I, Slyusarenko M, Sidina E, Nikiforova N, Semiglazov V, Semiglazova T, Aigner A, Rybakov E, Malek A. Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer. Cancers (Basel). 2021 Aug 03;13(15). doi: 10.3390/cancers13153905. PMID: 34359806; PMCID: PMC8345452.
Copy Download .nbib Format: NLM
[Cytogenetic check-up and treatment of cancer patients].

Voprosy onkologii

Monakhov AS, Semiglazov VF, Vagner RI, Guliaev AV, Anisimov VV, Barchuk AS.
PMID: 19069468
Vopr Onkol. 2008;54(5):565-72.

No abstract available.

Cite
Monakhov AS, Semiglazov VF, Vagner RI, et al. [Cytogenetic check-up and treatment of cancer patients]. Vopr Onkol. 2008;54(5):565-72
Monakhov, A. S., Semiglazov, V. F., Vagner, R. I., Guliaev, A. V., Anisimov, V. V., & Barchuk, A. S. (2008). [Cytogenetic check-up and treatment of cancer patients]. Voprosy onkologii, 54(5), 565-72.
Monakhov, A S, et al. "[Cytogenetic check-up and treatment of cancer patients]." Voprosy onkologii vol. 54,5 (2008): 565-72.
Monakhov AS, Semiglazov VF, Vagner RI, Guliaev AV, Anisimov VV, Barchuk AS. [Cytogenetic check-up and treatment of cancer patients]. Vopr Onkol. 2008;54(5):565-72. Russian. PMID: 19069468.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries